Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Phase 2 Completed 73 enrolled Otsuka Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.

Timeline

Start: 2017-01
Primary completion: 2017-06
Completion: 2017-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Difamilast	Small molecule	0.3 %	Topical
Subject	Difamilast	Small molecule	1 %	Topical

Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Summary

Timeline

Drugs

Indications